Show simple item record

dc.contributor.authorIriemenam, Nnaemeka C
dc.contributor.authorIge, Fehintola A
dc.contributor.authorGreby, Stacie M
dc.contributor.authorMpamugo, Augustine
dc.contributor.authorAbubakar, Ado G
dc.contributor.authorDawurung, Ayuba B
dc.contributor.authorEsiekpe, Mudiaga K
dc.contributor.authorThomas, Andrew N
dc.contributor.authorOkoli, Mary U
dc.contributor.authorAwala, Samuel S
dc.contributor.authorUgboaja, Blessing N
dc.contributor.authorAchugbu, Chicago C
dc.contributor.authorOdoh, Ifeanyichukwu
dc.contributor.authorNwatu, Felicia D
dc.contributor.authorOlaleye, Temitope
dc.contributor.authorAkayi, Loveth
dc.contributor.authorAkinmulero, Oluwaseun O
dc.contributor.authorDattijo, Joseph
dc.contributor.authorOnokevbagbe, Edewede
dc.contributor.authorOkunoye, Olumide
dc.contributor.authorMba, Nwando
dc.contributor.authorAgala, Ndidi P
dc.contributor.authorUwandu, Mabel
dc.contributor.authorAniedobe, Maureen
dc.contributor.authorStafford, Kristen A
dc.contributor.authorAbimiku, Alash'le
dc.contributor.authorHamada, Yohhei
dc.contributor.authorSwaminathan, Mahesh
dc.contributor.authorOkoye, McPaul I
dc.contributor.authorSteinhardt, Laura C
dc.contributor.authorAudu, Rosemary
dc.date.accessioned2022-04-04T12:41:34Z
dc.date.available2022-04-04T12:41:34Z
dc.date.issued2022-04-01
dc.identifier.urihttp://hdl.handle.net/10713/18446
dc.description.abstractObjective: There is a need for reliable serological assays to determine accurate estimates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence. Most single target antigen assays have shown some limitations in Africa. To assess the performance of a multi-antigen assay, we evaluated a commercially available SARS-CoV-2 Multi-Antigen IgG assay for human coronavirus disease 2019 (COVID-19) in Nigeria. Methods: Validation of the xMAP SARS-CoV-2 Multi-Antigen IgG assay was carried out using well-characterized SARS-CoV-2 reverse transcription polymerase chain reactive positive (97) and pre-COVID-19 pandemic (86) plasma panels. Cross-reactivity was assessed using pre-COVID-19 pandemic plasma specimens (213) from the 2018 Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS). Results: The overall sensitivity of the xMAP SARS-CoV-2 Multi-Antigen IgG assay was 75.3% [95% CI: 65.8%- 82.8%] and specificity was 99.0% [95% CI: 96.8%- 99.7%]. The sensitivity estimate increased to 83.3% [95% CI: 70.4%- 91.3%] for specimens >14 days post-confirmation of diagnosis. However, using the NAIIS pre-pandemic specimens, the false positivity rate was 1.4% (3/213). Conclusions: Our results showed overall lower sensitivity and a comparable specificity with the manufacturer's validation. There appears to be less cross-reactivity with NAIIS pre-pandemic COVID-19 specimens using the xMAP SARS-CoV-2 Multi-Antigen IgG assay. In-country SARS-CoV-2 serology assay validation can help guide the best choice of assays in Africa.en_US
dc.description.urihttps://doi.org/10.1371/journal.pone.0266184en_US
dc.language.isoenen_US
dc.publisherPublic Library of Scienceen_US
dc.relation.ispartofPLoS ONEen_US
dc.titleValidation of xMAP SARS-CoV-2 Multi-Antigen IgG assay in Nigeria.en_US
dc.typeArticleen_US
dc.identifier.doi10.1371/journal.pone.0266184
dc.identifier.pmid35363818
dc.source.journaltitlePloS one
dc.source.volume17
dc.source.issue4
dc.source.beginpagee0266184
dc.source.endpage
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record